Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAJRK1626

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 4	MAY 10	CA/CAplus enhanced with 1900-1906 U.S. patent records
NEWS 5	MAY 11	KOREAPAT updates resume
NEWS 6	MAY 19	Derwent World Patents Index to be reloaded and enhanced
NEWS 7	MAY 30	IPC 8 Rolled-up Core codes added to CA/CAplus and USPATFULL/USPAT2
NEWS 8	MAY 30	The F-Term thesaurus is now available in CA/CAplus
NEWS 9	JUN 02	The first reclassification of IPC codes now complete in INPADOC
NEWS 10	JUN 26	TULSA/TULSA2 reloaded and enhanced with new search and and display fields
NEWS 11	JUN 28	Price changes in full-text patent databases EPFULL and PCTFULL
NEWS 12	JUl 11	CHEMSAFE reloaded and enhanced
NEWS 13	JUl 14	FSTA enhanced with Japanese patents
NEWS 14	JUl 19	Coverage of Research Disclosure reinstated in DWPI
NEWS 15	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS 16	AUG 28	ADISCTI Reloaded and Enhanced
NEWS 17	AUG 30	CA(SM)/CAplus(SM) Austrian patent law changes
NEWS 18	SEP 11	CA/CAplus enhanced with more pre-1907 records
NEWS 19	SEP 21	CA/CAplus fields enhanced with simultaneous left and right truncation
NEWS 20	SEP 25	CA(SM)/CAplus(SM) display of CA Lexicon enhanced
NEWS 21	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS 22	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS 23	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme

NEWS EXPRESS	JUNE 30 CURRENT WINDOWS VERSION IS V8.01b, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 26 JUNE 2006.
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8
NEWS X25	X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:07:12 ON 10 OCT 2006

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 12:07:23 ON 10 OCT 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 9 OCT 2006 HIGHEST RN 910025-51-3
DICTIONARY FILE UPDATES: 9 OCT 2006 HIGHEST RN 910025-51-3

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10539451\Struc 1.str



chain nodes :
7 8 18 19 20
ring nodes :
1 2 3 4 5 6 9 10 11 12 13 14 15 16 17
chain bonds :
2-7 5-8 5-9 13-18 18-19 18-20

10539451.trn

ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 9-10 9-13 10-11 11-12 11-14 12-13 12-17 14-15
15-16 16-17
exact/norm bonds :
1-2 1-6 2-3 2-7 3-4 4-5 5-6 5-8 9-10 9-13 10-11 12-13 13-18 18-19
18-20
exact bonds :
5-9
normalized bonds :
11-12 11-14 12-17 14-15 15-16 16-17

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:Atom 10:Atom
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:CLASS 19:CLASS
20:CLASS

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> l1
SAMPLE SEARCH INITIATED 12:07:38 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 42 TO ITERATE

100.0% PROCESSED 42 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 452 TO 1228
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

```
=> l1 full
FULL SEARCH INITIATED 12:07:41 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED -      811 TO ITERATE

100.0% PROCESSED      811 ITERATIONS                                  14 ANSWERS
SEARCH TIME: 00.00.01

L3            14 SEA SSS FUL L1

=> file medline caplus
COST IN U.S. DOLLARS                                  SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     166.94     167.15

FILE 'MEDLINE' ENTERED AT 12:08:00 ON 10 OCT 2006

FILE 'CAPLUS' ENTERED AT 12:08:00 ON 10 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> l3
L4            4 L3

=> dup rem l4
PROCESSING COMPLETED FOR L4
L5             4 DUP REM L4 (0 DUPLICATES REMOVED)

=> d ibib abs hitstr 1-4

L5   ANSWER 1 OF 4  CAPLUS  COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER:         2006:565548  CAPLUS
DOCUMENT NUMBER:          145:224440
TITLE:                    Antitumor quinols: Role of glutathione in modulating
                          quinol-induced apoptosis and identification of
                          putative cellular protein targets
AUTHOR(S):                Chew, Eng-Hui; Matthews, Charles S.; Zhang, Jihong;
                          McCarroll, Andrew J.; Hagen, Thilo; Stevens, Malcolm
                          F. G.; Westwell, Andrew D.; Bradshaw, Tracey D.
CORPORATE SOURCE:         Centre for Biomolecular Sciences, School of Pharmacy,
                          University of Nottingham, Nottingham, UK
SOURCE:                   Biochemical and Biophysical Research Communications
                          (2006), 346(1), 242-251
                          CODEN: BBRCA9; ISSN: 0006-291X
PUBLISHER:                Elsevier
DOCUMENT TYPE:            Journal
LANGUAGE:                 English
AB   Novel heteroarom. quinols 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-
     dienone (1) and 4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-
     dienone (2) are promising novel anticancer agents.  They exhibit in vitro
     antiproliferative activity against colon, renal, and breast carcinoma cell
     lines as well as in vivo antitumor activity in colon, renal, and breast
     tumor xenografts.  Elucidation of the mechanism of antitumor action of
     these compds. is of great importance.  We show in this study that the
     compds. induced apoptosis as demonstrated by caspase 3 and PARP cleavage
     at doses causing G2/M cell cycle arrest.  Glutathione was found to play an
     important role in modulating quinol-mediated cytotoxicity.  In HCT 116
     cells, treatment with 1 and 2 caused a 2- to 3-fold increase in the total
     glutathione content, suggestive of a glutathione-mediated antioxidant
     response.  Indeed, buthionine sulfoximine (BSO)-induced glutathione
```

depleted cells were 6-10 times more sensitive to 1 and 2, while glutathione monoethyl ester supplementation decreased the antitumor potencies by 2-3 times. In further studies we determined other cellular proteins which bind to an immobilized quinol analog, and identified several proteins including β-tubulin, heat shock protein 60, and peroxiredoxin 1 as potential mol. targets of quinols that may contribute to their proapoptotic and antiproliferative effects.

IT 719308-90-4
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antitumor quinols and role of glutathione in modulating quinol-induced apoptosis and identification of putative cellular protein targets)

RN 719308-90-4 CAPLUS

CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(phenylsulfonyl)-(9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2005:375723 CAPLUS

DOCUMENT NUMBER: 143:38034

TITLE: Elucidation of thioredoxin as a molecular target for antitumor quinols

AUTHOR(S): Bradshaw, Tracey D.; Matthews, Charles S.; Cookson, Jennifer; Chew, Eng-Hui; Shah, Manish; Bailey, Kevin; Monks, Anne; Harris, Erik; Westwell, Andrew D.; Wells, Geoffrey; Laughton, Charles A.; Stevens, Malcolm F. G.

CORPORATE SOURCE: Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, UK

SOURCE: Cancer Research (2005), 65(9), 3911-3919
CODEN: CNREA8; ISSN: 0008-5472

PUBLISHER: American Association for Cancer Research

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Heteroarom. quinols 4-(benzothiazol-2-yl)-4-hydroxycyclohexa-2,5-dienone (1) and 4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-dienone (2) exhibit potent and selective antitumor activity against colon, renal, and breast carcinoma cell lines in vitro (GI50 < 500 nmol/L). In vivo growth inhibition of renal, colon, and breast xenografts has been observed Profound G2-M cell cycle block accompanied down-regulation of cdk1 gene transcription was corroborated by decreased CDK1 protein expression following treatment of HCT 116 cells with growth inhibitory concns. of 1 or 2. The chemical structure of the quinol pharmacophore 4-(hydroxycyclohexa-2,5-dienone) suggested that these novel agents would readily react with nucleophiles in a double Michael (β-carbon) addition Indeed, COMPARE anal. within the National Cancer Institute database revealed a number of chemical related quinone derivs. that could potentially react with sulfur nucleophiles in a similar manner and suggested that

thioredoxin/thioredoxin reductase signal transduction could be a putative target. Mol. modeling predicted covalent irreversible binding between quinol analogs and cysteine residues 32 and 35 of thioredoxin, thereby inhibiting enzyme activity. Binding has been confirmed, via mass spectrometry, between reduced human thioredoxin and I. Microarray analyses of untreated HCT 116 cells and those exposed to either 1 (1 μmol/L) or 2 (500 nmol/L and 1 μmol/L) determined that of ≥10,000 cancer-related genes, expression of thioredoxin reductase was up-regulated >3-fold. Furthermore, quinols 1 and 2 inhibited insulin reduction, catalyzed by thioredoxin/thioredoxin reductase signaling in a dose-dependent manner (IC50 < 6 μmol/L). Results are consistent with a mechanism of action of novel antitumor quinols involving inhibition of the small redox protein thioredoxin.

IT 719308-90-4
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(elucidation of thioredoxin as mol. target for antitumor quinols)

RN 719308-90-4 CAPLUS

CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2004:1142024 CAPLUS

DOCUMENT NUMBER: 142:219117

TITLE: Quinols as Novel Therapeutic Agents. 2. 4-(1-Arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones and Related Agents as Potent and Selective Antitumor Agents

AUTHOR(S): Berry, Jane M.; Bradshaw, Tracey D.; Fichtner, Iduna; Ren, Ruobo; Schwalbe, Carl H.; Wells, Geoffrey; Chew, Eng-Hui; Stevens, Malcolm F. G.; Westwell, Andrew D.

CORPORATE SOURCE: Cancer Research U.K. Experimental Cancer Chemotherapy Research Group, Centre for Biomolecular Sciences, School of Pharmacy, University of Nottingham, Nottingham, NG7 2RD, UK

SOURCE: Journal of Medicinal Chemistry (2005), 48(2), 639-644
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 142:219117

GI



I II III IV

AB A series of substituted 4-(1-arylsulfonylindol-2-yl)-4-hydroxycyclohexa-2,5-dien-1-ones (indolylquinols) I (R = H, 5-OMe, 5-F, 6-F; R1 = H, 4-Me, 4-OMe, 2,4,6-triisopropyl) was synthesized on the basis of the discovery of lead compound I (R = R1 = H) and screened for antitumor activity. I was synthesized via the "one-pot" addition of lithiated (arylsulfonyl)indoles II to 4,4-dimethoxycyclohexa-2,5-dienone followed by deprotection under acidic conditions. Similar methodol. gave rise to the related naphtho-substituted quinols III (R1 = H, Me), 1H-indole- and benzimidazole-substituted quinols IV (X = CH, N). A number of compds. in this new series were found to possess in vitro human tumor cell line activity substantially more potent than the recently reported antitumor 4-substituted 4-hydroxycyclohexa-2,5-dien-1-ones with similar patterns of selectivity against colon, renal, and breast cell lines. I (R = 6-F, R1 = H), the most potent compound in the series in vitro, exhibited a mean GI50 = 16 nM and a mean LC50 = 2.24 μM in the NCI 60-cell-line screen, with LC50 activity in the HCT 116 human colon cancer cell line below 10 nM. The crystal structure of the unsubstituted indolylquinol I (R = R1 = H) exhibited two independent mols., both participating in intermol. hydrogen bonds from quinol OH to carbonyl O, but one OH group also interacts intramolecularly with a sulfonyl O atom. This interaction, which strengthens upon ab initio optimization, may influence the chemical environment of the bioactive quinol moiety. In vivo, significant antitumor activity was recorded (day 28) in mice bearing s.c. implanted MDA-MB-435 xenografts, following i.p. treatment of mice with I (R = R1 = H) at 50 mg/kg.

IT 719308-90-4P
RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(crystal structure; preparation and biol. activity of (arylsulfonylindolyl)hydroxycyclohexadienones as selective and potent antitumor agents)

RN 719308-90-4 CAPLUS

CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



IT 719308-91-5P 719308-92-6P 719308-93-7P
719308-94-8P 719308-95-9P 719308-96-0P
719308-98-2P 719308-99-3P 719309-00-9P
840474-95-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and biol. activity of (arylsulfonylindolyl)hydroxycyclohexadienones as selective and potent antitumor agents)

RN 719308-91-5 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-5-methoxy-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719308-92-6 CAPLUS
CN 1H-Indole, 5-fluoro-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719308-93-7 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 719308-94-8 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 719308-95-9 CAPLUS
CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)- (9CI) (CA INDEX NAME)



RN 719308-96-0 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719308-98-2 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 719308-99-3 CAPLUS
CN 1H-Indole, 2-(1,4-dihydro-1-hydroxy-4-oxo-1-naphthalenyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)





RN 719309-00-9 CAPLUS
CN 1H-Indole, 2-(1,4-dihydro-1-hydroxy-4-oxo-1-naphthalenyl)-1-[(4-

methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 840474-95-5 CAPLUS
CN 1H-Indole, 6-fluoro-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:550875 CAPLUS
DOCUMENT NUMBER: 141:106370
TITLE: Preparation of 4-[1-(sulfonyl)-1H-indol-2-yl]-4-(hydroxy)-cyclohexa-2,5-dienone compounds and analogs thereof as therapeutic agents
INVENTOR(S): Stevens, Malcolm Francis Graham; Westwell, Andrew David; Poole, Tracey Dawn; Wells, Geoffrey; Berry, Jane Marie
PATENT ASSIGNEE(S): Cancer Research Technology Limited, UK
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004056361	A1	20040708	WO 2002-GB5842	20021220

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2508275	AA	20040708	CA 2002-2508275	20021220
AU 2002353193	A1	20040714	AU 2002-353193	20021220
EP 1572197	A1	20050914	EP 2002-788211	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015986	A	20051101	BR 2002-15986	20021220
CN 1717233	A	20060104	CN 2002-830081	20021220
JP 2006512351	T2	20060413	JP 2004-561588	20021220
US 2006100265	A1	20060511	US 2005-539451	20050620
PRIORITY APPLN. INFO.:			WO 2002-GB5842 W	20021220

OTHER SOURCE(S): MARPAT 141:106370

GI



I



II

AB This invention pertains to certain 4-(1-(sulfonyl)-1H-indol-2-yl)-4-(hydroxy)-cyclohexa-2,5-dienone compds., and analogs thereof, including compds. of the formula I [wherein Ar = 1-(sulfonyl)-1H-indol-2-yl; the bond marked α is a single bond or a double bond; the bond marked β is a single bond or a double bond; OR1 = OH, ether group (e.g., OMe) or acyloxy (i.e., reverse ester) group (e.g., -OC(O)Me); R2, R3, R5, R6 = H, monovalent monodentate substituent or a ring substituent which, together with an adjacent ring substituent, and together with the ring atoms to which these ring substituents are attached, form a fused ring; and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof] which are, inter alia, antiproliferative agents, anticancer agents, and/or thioredoxin/thioredoxin reductase inhibitors. Syntheses of 11 representative compds. I are described. Thus, reacting 4,4-dimethoxycyclohexa-2,5-dienone (preparation given) with 1-benzenesulfonyl-1H-indole afforded 18% II 4-(1-benzenesulfonyl-1H-indol-2-yl)-4-hydroxycyclohexa-2,5-dienone which showed IC50 of 0.086 μM and 0.259 μM against HCT 116 and HT 29 growth (in vitro), resp. The present invention also pertains to pharmaceutical compns. comprising compds. I, and the use of such compds. I and compns., both in vitro and in vivo, for example, in the treatment of proliferative conditions, (e.g., cancer), and/or conditions mediated by thioredoxin/thioredoxin reductase.

IT 719308-90-4P 719308-91-5P 719308-92-6P
719308-93-7P 719308-94-8P 719308-95-9P
719308-96-0P 719308-97-1P 719308-98-2P
719308-99-3P 719309-00-9P 719309-01-0P
719309-02-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(preparation of 4-[1-(sulfonyl)-1H-indol-2-yl]-4-(hydroxy)-cyclohexa-2,5-dienone compds. and analogs thereof as antitumor agents)

RN 719308-90-4 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719308-91-5 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-5-methoxy-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719308-92-6 CAPLUS
CN 1H-Indole, 5-fluoro-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719308-93-7 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 719308-94-8 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 719308-95-9 CAPLUS
CN 1H-Indole, 1-[(4-fluorophenyl)sulfonyl]-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)- (9CI) (CA INDEX NAME)



RN 719308-96-0 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)



RN 719308-97-1 CAPLUS
CN 1H-Indole, 5-fluoro-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 719308-98-2 CAPLUS
CN 1H-Indole, 2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)-1-[[2,4,6-tris(1-methylethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 719308-99-3 CAPLUS
CN 1H-Indole, 2-(1,4-dihydro-1-hydroxy-4-oxo-1-naphthalenyl)-1-(phenylsulfonyl)- (9CI) (CA INDEX NAME)





RN 719309-00-9 CAPLUS
CN 1H-Indole, 2-(1,4-dihydro-1-hydroxy-4-oxo-1-naphthalenyl)-1-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 719309-01-0 CAPLUS
CN 1H-Indole, 1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)- (9CI) (CA INDEX NAME)



RN 719309-02-1 CAPLUS

CN 1H-Indole, 1-[[4-[3-(dimethylamino)propoxy]phenyl]sulfonyl]-2-(1-hydroxy-4-oxo-2,5-cyclohexadien-1-yl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	22.49	189.64
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-3.00	-3.00

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:10:00 ON 10 OCT 2006